A BSTRACT
In developing and manufacturing protein biopharmaceuticals, aggregation is a parameter that needs careful monitoring to ensure the quality and consistency of the fi nal biopharmaceutical drug product. The analytical method of choice used to perform this task is size-exclusion chromatography (SEC). However, it is becoming more and more apparent that considerable care is required in assessing the accuracy of SEC data. One old analytical tool that is now reappearing to help in this assessment is analytical ultracentrifugation (AUC). Developments in AUC hardware and, more importantly, recent developments in AUC data analysis computer programs have converged to provide this old biophysical tool with the ability to extract very high resolution size information about the molecules in a given sample from a simple sedimentation velocity experiment. In addition, AUC allows sample testing to be conducted in the exact or nearly exact liquid formulation or reconstituted liquid formulation of the biopharmaceutical in the vial, with minimal surface area contact with extraneous materials. As a result, AUC analysis can provide detailed information on the aggregation of a biopharmaceutical, while avoiding many of the major problems that can plague SEC, thus allowing AUC to be used as an orthogonal method to verify SEC aggregation information and the associating properties of biopharmaceuticals.
INTRODUCTION
In the development of biopharmaceuticals, which are predominately protein-based compounds, the problem of aggregation looms as a key point of concern to scientists involved in cell culture, purifi cation, and formulation. Hence, having appropriate analytical tools that are capable of detecting and quantifying biopharmaceutical aggregates is important. Although several analytical techniques are available to potentially provide this information, sizeexclusion chromatography (SEC) is the method of choice. Its ease of use, the simplicity of its physical separation mechanism, its ability to measure low levels of aggregation with very small amounts of material, and the high speed in which separations occur, using relatively simple hardware, yield an inexpensive technique with high sample throughput. In most cases, SEC works well, achieving good size separations and valid aggregation information with high precision. Nevertheless, despite these positive attributes, care still must be exercised in assessing the validity of SEC data. When inaccuracies occur it is frequently because of the nonspecifi c interactions of the biopharmaceutical and its aggregates with the chromatographic material in the high performance liquid chromatography (HPLC) column or the HPLC-column hardware, especially the column frits. [1] [2] [3] [4] [5] To confi rm the accuracy of SEC data, analytical ultracentrifugation [6] [7] [8] [9] [10] (AUC) can now be used. In addition, AUC can serve as an important characterization tool for studying the biophysical solution properties of a biopharmaceutical and its aggregates when SEC analysis is not feasible or when a direct assessment of the state of aggregation of a biopharmaceutical in the initial sampled vial is desired. This latter point is important because the SEC mobile phase frequently does not correspond to the initial liquid formulation of the biopharmaceutical being analyzed. In addition, during SEC, the initial concentration of the injected biopharmaceutical is greatly reduced. Such changes in the chemical environment of a biopharmaceutical during SEC may alter the true state of aggregation of a biopharmaceutical sample, especially when reversible concentration-dependent aggregation is present. Hence, this article will highlight the new capabilities of AUC analysis and speculate on the important role AUC will play in the biopharmaceutical industry in terms of measuring aggregation.
ANALYTICAL ULTRACENTRIFUGES
The development and use of the analytical ultracentrifuge in studying the solution behavior of macromolecules dates back to the early twentieth century. This early work is highlighted by the pioneering efforts of Svedberg and his ture, 71 and the reactivity of some of its chemical constituents 67 , 72 , 73 ). In the case of biopharmaceuticals, the additional sources of physical handling, processing, and exposure of proteins to an array of different physical and chemical environments offer more opportunities for altering proteins ' structure that may further enhance their ability to aggregate. If the production of these unwanted aggregates is not minimized and they are not removed, they will become part of the fi nished biopharmaceutical drug product and may alter the activity of the biopharmaceutical and cause adverse biological effects when administered to a patient (eg, immunogenicity). [74] [75] [76] Even the simple process of concentrating a biopharmaceutical can cause aggregation by driving specifi c and nonspecifi c interactions through mass action. 77 Although such aggregation can be reversible, the kinetics of the disassociation process may be very slow. 78 When these aggregated biopharmaceuticals are dosed into a patient, the slow disassociation process may be further altered because of the unique physical and chemical environment found in vivo, which can produce molecular crowding effects 33 , 79-82 (resulting from the very high macromolecular concentration environment of the fl uids in the circulatory system and in the liquids found within and between cells) and charge effects (resulting from changes in ionic strength and pH). Hence, the simple and rapid disassociation of these types of aggregates from drug dilution during its administration may not mirror in vitro observations. As a result, the average lifetime of the reversible concentration-dependent aggregate within a patient could be increased signifi cantly. Such behavior may lead to problems.
In characterizing the aggregation of a biopharmaceutical the initial amount of aggregation, the initial distribution of aggregate sizes (which describes the amount of material present with a specifi c number and arrangement of repeating monomer units), and changes in both these parameters with time, formulation matrix, and storage conditions is of great important. In particular, information concerning aggregation size appears to play an important role in protein immunogenicity. [83] [84] [85] [86] Hence, even when the total amount of aggregation remains unchanged, changes in the size distribution of the aggregated biopharmaceutical still need to be carefully monitored.
SIZE-EXCLUSION CHROMATOGRAPHY
The positive attributes of SEC, mentioned in the introduction, have made SEC the biopharmaceutical industry ' s method of choice for detecting and quantifying the aggregation of biopharmaceuticals. Nevertheless, these highly favorable attributes must be weighted against the following issues, some of which have already been briefl y mentioned:
1. SEC analysis is frequently conducted using a mobile phase that is signifi cantly different from the buffer coworkers. 11 From this early period of time up until the 1970s AUC played an important role in formulating our knowledge of the biophysical properties of biopolymers (eg, protein, nucleic acid), supramolecular structures such as viruses and ribosomes, and synthetic polymers. Hence, for our early basic understanding of macromolecular structure and molecular biology we are signifi cantly indebted to this important analytical instrument (details concerning the history of the analytical ultracentrifuge can be found in Lewis and Weiss, 12 
AGGREGATION OF PROTEIN BIOPHARMACEUTICALS
A unique characteristic of proteins is their ability to aggregate with themselves (self-association), other proteins, or other chemical compounds (hetero-association) in specifi c ways to create a multitude of stable and dynamic biological structures. These specifi c spontaneous associations or aggregations of proteins (to form functional biological structures) are frequently referred to as self-assembly and can be reversible or irreversible. During the biosynthesis of proteins, and their existence within or outside the cell, opportunities exist for their misfolding, denaturation, and chemical (enzymatic and nonenzymatic) modifi cation. These events can lead to unwanted nonspecifi c protein aggregation [67] [68] [69] [70] (which predominately results from the weak forces that hold a protein structure together, the dynamic nature of a protein ' s struc-matrix of the biopharmaceutical sample being studied. (In some cases, mobile phases may even contain organic solvents.) Such differences can alter the amount and the size distribution of the aggregation initially in a sample. This difference between a sample ' s matrix and the SEC mobile phase occurs for the following reasons:
○ The suppression of interactions of the biopharmaceuticals with the SEC chromatography material.
○ The need to run many samples in different buffer matrices in a short time. In this situation the use of a different SEC mobile phase to match each sample matrix buffer is impractical because of the large amount of time and labor it would require to re-equilibrate the HPLC system and, more importantly, may not be feasible because of interactions of the biopharmaceutical with the SEC chromatography material.
○ The lack of knowledge by the investigator of the possible changes that may occur to a sample ' s aggregation level and its distribution of sizes when the chemical environment of a sample is changed during SEC.
2. Sample preparation steps that include sample dilution and sample clarifi cation are typically required before injecting a biopharmaceutical on an SEC column. Such sample treatments can alter the amount and the size distribution of aggregation initially in a sample. In the case of sample dilution, the ability to detect reversible concentration-dependent aggregation is signifi cantly reduced. In the case of clarifying SEC samples (especially when membrane fi lters are used to prevent column fouling), the removal or selective removal of specifi c biopharmaceutical species (eg, aggregated material) may occur.
3. SEC columns and column hardware can frequently require conditioning before actual testing (using either the biopharmaceutical itself or another general protein, eg, bovine serum albumin) to eliminate the interaction of the biopharmaceutical with active sites in the SEC column or on the HPLC hardware. The masking of these active sites (which can vary from one lot of SEC material to another) is of critical importance in avoiding the total or selective removal of material, such as aggregates, from the injected biopharmaceutical sample. However, once an SEC column is conditioned, the secondary issue of the stability of this conditioning becomes another point of concern.
4. The need to have other reliable and orthogonal methods to confi rm (qualifi ed or validated) the accuracy of the amount of aggregation and its distribution of aggregate sizes measured by SEC.
5. The separation range of SEC columns may not be large enough to resolve aggregated material from the biopharmaceutical monomer or may provide limited information about the size distribution of the aggregates present. This problem arises when the pore size range in commercially available SEC chromatography material is too small in comparison to the actual size of the biopharmaceutical monomer and/or its aggregates.
ANALYTICAL ULTRACENTRIFUGATION, " BOUNDARY " SEDIMENTATION VELOCITY
AUC experiments typically fall into 2 categories: sedimentation velocity or sedimentation equilibrium. This article focuses on only sedimentation velocity. Discussion of AUC and sedimentation equilibrium can be found elsewhere. 59 , 87 Nevertheless, it should noted that in many cases the application of both types of sedimentation experiments can be very helpful in gaining an understanding of the biophysical solution properties of a protein system.
In conducting classical " boundary " sedimentation velocity experiments, a double sector-shaped centerpiece is commonly used. The fi rst sector is fi lled with a sample solution, while the second is fi lled with a reference solution. (For UV detection it is possible to eliminate the reference solution, allowing the reference sector to be used as a second sample. 88 As a result, the number of samples that can be handled in one sedimentation velocity run can be doubled.) Acceleration of this cell to an appropriate speed and the acquisition of concentration data as a function of radius, r, at different times, t, yield a series of concentration profi les, s(r, t), that reveals the complete migration pattern of all the different macromolecular species in a given sample. A theoretical example displaying a few of these concentration profi les that would be obtained for a monodisperse sample during a sedimentation velocity experiment is shown in Figure 1 . In this case, each concentration profi le consists of a region that displays a single sigmoidal-shaped curve that is called the boundary and a fl at region at a greater radial distance from the boundary that is called the plateau. Concentration profi les obtained at later times show progressive boundary broadening and a reduction in the height of the plateau. The reduction in the plateau height is due to the sector shape of the cell (required to avoid convection resulting from the radial nature of the centrifugal force fi eld 89 ), while the sigmoidal-shape boundary and its broadening is due to diffusion. In 1929, Lamm 90 developed the partial differential equation that enables calculation of the radial-concentration profi le and the change in this concentration profi le with time, s(r, t), for a monodisperse sample in a centrifugal fi eld in a sector-shaped cell, using the sedimentation and diffusion coeffi cients of the material being studied. Unfortunately, this equation has no known general analytical solution, except for some very special cases. 91 As a result, until recently, relatively little general use has been made of this equation for routine sedimentation velocity analysis. For many years, sedimentation velocity experiments were simply conducted and analyzed to obtain the sedimentation coeffi cient of a sample, 92 as shown in Figure 2 . In addition, preliminary qualitative assessment of a sample ' s high level of homogeneity was frequently demonstrated by sedimentation velocity experiments that showed the visual presence of only a single migrating boundary ( Figure 3C shows that this boundary is not a rigorous criterion for assessing a sample ' s homogeneity).
MODERN SEDIMENTATION VELOCITY ANALYSIS
It is important to note that sedimentation velocity experiments in an analytical ultracentrifuge are conducted under very well controlled experimental conditions (temperature, centrifugal fi eld (rotor speed), and defi ned and fi xed geometry), with minimal sample contact with surfaces and with no sample manipulation or sample preparation steps other than possibly sample dilution. A sample can be taken directly from the sample vial and placed into the assembled AUC cell. (This sample management approach is particularly applicable when UV detection is used. However, the use of refractometric detection [interference optics] frequently requires some minor sample treatment; see the brief discussion on sample treatment in the Advantages of Using AUC to Help Assess Biopharmaceutical Aggregation section.) Furthermore, the underlying physics and equations that explain the movement of the molecules in these experiments are well understood. All of this, combined with the automated data acquisition capability of the modern analytical ultracentrifuge and the recent availability of powerful desktop computers, has provided the opportunity for several investigators to develop advanced numerical analysis computer programs for the analysis of sedimentation velocity experiments. 7 , 8 , 35 , 36 , 38 , 40 , 47 , 48 , 51 , 54 , 58 These software programs now offer signifi cant capability to extract information from sedimentation velocity experiments that was either not feasible or far too diffi cult to do in the past. In this article, we will focus on one of the more recent AUC computer programs called SEDFIT, developed by Schuck and coworkers. 8 , 51 , 54 Recently Schuck and coworkers have developed a second computer program for AUC analysis called SEDPHAT. 58 , 59 This second program offers signifi cantly more advanced capabilities for analyzing AUC data by enabling global analysis procedures to be applied to several different types of experiments to extract more detailed and reliable information about a particular macromolecular system. Discussion of this program, Figure 1 . Theoretically calculated concentration profi les, s(r, t), generated for a simulated sedimentation velocity run on a sample containing only 1 molecular component with a molecular weight of 150 kDa and a sedimentation coeffi cient value of 6.5 S. The area in the fi rst concentration profi le, labeled A, corresponds to the region in the concentration profi le called the boundary, while the area labeled B corresponds to the region in the concentration profi le called the plateau. All analytical ultracentrifugation concentration profi les were generated using SEDFIT with a time interval of 2000 seconds. The profi les were calculated for a sedimentation velocity experiment conducted at a speed of 50 000 rpm, at 20°C, with a noise level of 0.01. The corresponding concentration profi les that would be obtained in the absence of diffusion are indicated by the traces (with no noise) in red. Points labeled C correspond to the radial position in the boundary region equal to the half-height of the plateau region for each concentration profi le. These points would be used to calculate the sedimentation coeffi cient of the sample ( Figure 2 ).
Figure 2.
A typical plot of the natural log of the radial boundary position (which usually corresponds to the radial position in the boundary that equals the half-height of the plateau region) of each concentration profi le as a function of time, in seconds, multiplied by the angular velocity, radian per second, squared. The slope of this plot yields the sedimentation coeffi cient of the molecular species in the sample. If more than one species were in the sample, the sedimentation coeffi cient would correspond to a weight-average sedimentation coeffi cient, S w . Technically, for the slope to accurately correspond to the sedimentation coeffi cient of the sample, the radial position of the boundary used should be equal to the square root of the second moment of the boundary. 93 However, in many cases the difference between the radial position corresponding to the square root of the second moment of the boundary and the radial position in the boundary that corresponds to the half-height of the plateau is too small to be signifi cant. One of the important capabilities of SEDFIT is its ability to extract information concerning the amount and the distribution of aggregate sizes in a sample. The brief discus- sion provided below attempts to outline some of the very basic approaches used in this computer program. However, the reader is advised to consult recent reviews by Balbo and Schuck, 94 , 95 Dam and Schuck, 8 and Lebowitz et al, 7 and the original publications of Schuck and his collaborators, [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] to acquire a more complete understanding of the operation, capabilities, and limitations of this AUC analysis program.
Returning to the data in Figure 1 , for a monodisperse sample, and assuming for a moment that the concentration profi les, s(r, t), in this fi gure are actually experimental data, an approach could be taken to numerically solve the Lamm equation, f(s, D, r, t). This could be achieved via numerical procedures that conduct a search for the sedimentation, s, and diffusion, D, coeffi cients (within a realistic constrained range of s and D values) that generate theoretical concentration profi les that best match the entire set of experimental concentration profi les, s(r, t), collected during an AUC experiment. If this numerical analysis is conducted under appropriate statistical criteria of goodness-of-fi t, which typical involves minimizing the sum of the squares of deviations between the experimental and theoretical data, as shown in Equation 1 below, useful molecular information concerning the sedimentation and diffusion coeffi cients and molecular weight of the single molecular component in the sample could be obtained.
The real utility of this approach, however, is in applying it to the more general problem of determining the level of homogeneity or the actual polydispersity of a real sample. 
Evaluation and plotting of the differential sedimentation distribution value, c(s) (which corresponds to the amount of material in a sample having a sedimentation coeffi cient between s and s + ds), vs s yields the distribution of sedimentation coeffi cients for the sample being analyzed. This plot gives information very similar to that provided by an SEC chromatogram, as shown in Figure 4 . From the c(s) vs s plot, the homogeneity of a sample can be assessed and the amount of each component determined by appropriate integration. It should be noted that in some cases the presence of different components in a sample can be seen in AUC concentration profi les, s(r, t), as separate resolved boundaries or as a sloping plateau. The occurrence of these visual clues, however, is very dependent on the differences in the sedimentation and diffusion coeffi cients between the components present and the relative number and amounts of each component ( Figures 3 and 5 ) .
The 8 ). The success of these calculations depends on fi nding the best weightaverage value for the translational frictional coeffi cient ratio, (f/f o ) w , for the entire sample. The ratio f/f o corresponds to the ratio of the translational frictional coeffi cient of a molecule relative to its theoretical translational frictional coeffi cient when the same molecule takes on the shape of a sphere of the same density. 8 It should be noted that the validity of applying the same (f/f o ) w value to all molecular components in a given sample has limitations. A discussion of this topic can be found in works by Dam and Schuck, 8 Philo, 10 Schuck, 51 , 54 and Schuck et al. 57 In the case of concept 2, which deals with the quality of the numerical fi t, asking for the highest fi delity to minimize the difference between the experimental data (with its accompanying noise) and the theoretical data can create artifacts (because the optimization search routine will force the theoretical data to match the experimental noise). However, too much of a reduction in the quality of the fi t between the experimental and theoretical data will also give misleading information by failing to appropriately match the " real " data. Hence, the task of fi nding just the right balance in the quality of fi t is important. In SEDFIT, the use of regularization (a mathematical tool that can control the fi tting process) with a confi dence level typically set at 0.7 is commonly recommended to achieve this goal 8 (the operator can adjust the confi dence level and therefore experiment with the level of regularization applied). For concept 3, all species must display ideal thermodynamic and hydrodynamic behavior. Such behavior includes the absence of excluded volume and electrostatic effects, and interactions/aggregation or changes in aggregation within the time scale of the sedimentation experiment. As a result, the absence of such non-ideality effects needs to be assessed. In most cases non-ideality can be avoided by using low sample concentrations (roughly 1 mg/mL or less) and making sure the salt concentration is high enough (roughly 0.05M or greater).
The numerical approach used by Schuck and coworkers to solve Equation 4 involves a collection of mathematical tools that include fi nite element analysis to numerically solve the Lamm equations guided by nonlinear least squares optimization calculations with appropriate regularization. These calculations, which are typically conducted to fi nd the best (f/f 0 ) w within a specifi ed (constrained) range and resolution of s values, may also involve the optimization of additional experimental parameters (initially set by the operator) at the same time. These other parameters include the radial positions of the sample solution meniscus and cell bottom. This modern approach of direct boundary modeling of the entire sedimentation velocity process requires far more data than did the older approach of sedimentation velocity analysis, which required only a few concentration profi les, as shown in Figure 6 .
The success and utility of this modern approach for extracting information from sedimentation velocity data are illustrated in the SEC vs AUC section, with real examples from my experience in using SEDFIT on a range of biopharmaceuticals. However, before discussing these examples it should be noted that the collection of constantly changing concentration profi les acquired during a sedimentation velocity experiment is a very rich and unique source of information. Hence, the fi tting of all the experimental data within a realistic limited range of s values and resolution of the s step size (set by the operator) puts signifi cant constraints on which models can be used to adequately fi t the data. The more the fi tting process can be constrained with information, the more accurate will be the information generated by the 
SEC VS AUC
When the form of sedimentation velocity analysis discussed in Modern Sedimentation Velocity Analysis is applied to the assessment of biopharmaceutical aggregation, the sensitivity (in terms of limit of quantifi cation), precision (in terms of repeatability, intermediate precision, and reproducibility), and accuracy of the results obtained by SEDFIT are important issues. Data shown in Figure 4 compare the SEC elution profi le with the calculated distribution of sedimentation coeffi cients obtained by AUC analysis conducted on the same samples, where the aggregation content varied from 1% to 12%. Appropriate integration of the resulting peak areas from these and other plots produced the aggregation information in Table 1 . These results indicate a good Figure 6 . (A) Classical amount of analytical ultracentrifugation (AUC) data required for determining the sedimentation coeffi cient of a sample from a sedimentation velocity experiment in comparison to (B) the modern approach of AUC data analysis, using SEDFIT, which requires large amounts of AUC data to accurately calculate the distribution of sedimentation coeffi cients, c(s), of a sample. The latter approach is now capable of extracting from a sedimentation velocity experiment the number and amounts of different species that are in the sample even when individual boundaries for each component are not visible (eg, Figure 3C ). † Value corresponds to % Dimer + % HMW. ‡ % Difference = 100 (ABS|SEC(n) − AUC(n)|/((SEC(n) + AUC(n))/2)), where SEC(n) and AUC(n) equal % Total Aggregation for sample n as measured by SEC and AUC, respectively. agreement between AUC and SEC over the aggregation range investigated. Hence, good sensitivity using AUC can be achieved down to aggregation levels of ~1% (using UV detection with absorbance loads in the range of ~0.4-1.2). In fact, Dam and Schuck state that their computer simulation work has shown that using " a set of profi les covering the complete sedimentation process at a signal-to-noise ratio of 200:1 (which can be readily achieved, eg, at a loading concentration of 0.3-0.4 mg/mL of protein in the interference optics), minor peaks consisting of 0.2% of the total protein concentration can be readily detected. " 8 However, it is the author's experience that efforts to quantify components below ~1% put considerable demands on the data and the data analysis process.
Data shown in Figure 7 provide additional information on the intermediate precision and comparability of SEC and AUC for a more highly aggregated and more complex sample. Quantitative SEC and AUC results obtained for this sample on 3 different days are shown in Table 2 . Again, results show good agreement and good precision. When a consistent level of agreement, as indicated in Tables 1 and  2 , is obtained between these 2 orthogonal methods, significant confi dence in the accuracy of SEC aggregation information is generated. In general, a level of agreement achieved in terms of total aggregation between AUC and SEC (expressed as percentage difference; Tables 1 and 2 ) that is about ± 10% to 20% or better is a tentative criterion used in our lab to indicate that SEC is providing adequate accuracy. It should be noted that this criterion is typically applied when the total aggregation level determined by AUC is 1% or higher. Nevertheless, the real clear-cut benefi t of AUC in assessing SEC methods is in cases where very large and consistent differences exist between these 2 methods, as illustrated in Figures 8 and 9 . Such situations typically highlight the utility of AUC in uncovering SEC problems or in revealing solution properties of biopharmaceuticals that SEC missed.
Results shown in Figures 4 and 7 also illustrate the ability of AUC to provide better resolution than SEC. This point is particularly highlighted in Figure 7 for the high -molecular Table 2 . Agg indicates aggregation.
weight (HMW) material. In the case of SEC, the HMW material piles up into a single excluded volume peak. In the case of AUC, this material is resolved to reveal a very heterogeneous collection of molecular species. Such resolution makes it possible to monitor changes in the HMW material that could not be detected by SEC. This higher resolution and enormous dynamic size range of AUC analysis is further demonstrated in Figure 10 . In this example, AUC is used to assess the homogeneity of an adenovirus gene therapy biopharmaceutical. Because of the large size of the monomer unit (which has a diameter of ~900 Å) and its aggregates, SEC cannot be used to monitor the aggregation and the distribution of the aggregate sizes in samples of this biopharmaceutical. However, AUC analysis conducted using the interference optics (which minimizes problems associated with differences in the response factor for different molecular components in this sample) at 3000 rpm provides the results shown in Figure 10 . In the case of samples A and B, the concentration profi les clearly reveal the presence of 2 boundaries. The small, slow-moving boundary seen (toward the end of the run) in both preparations corresponds to the peak labeled " empty capsid " in the c(s) vs s plot. This material is a common assembly impurity product made during normal adenovirus production 96 that is not removed during large-scale virus purifi cation. 97 The much larger and faster-moving boundary, seen in both cases, corresponds to the intact virus monomer and is labeled " monomer " in the c(s) vs s plot. All material mov- ing faster than the virus monomer represents other virus species that include adenovirus aggregates. Close inspection of the plateau region of the concentration profi les obtained for both virus preparations reveals that sample B contains a much higher level of faster-sedimenting material than sample A does. This difference can be seen by the greater sloping of the plateau region in concentration profi les for sample B than in concentration profi les for sample A. This visual observation is confi rmed by quantitative AUC analysis with SEDFIT, where the apparent aggregation value for sample A was determined to be ~4%, while the apparent aggregation value for sample B was determined to be ~23% (Berkowitz and Philo, unpublished data, August 15, 2006) .
Data shown in Figure 8 illustrate an issue frequently encountered in SEC: variability in the amount of SEC aggregation determined for the same sample as a result of using different SEC mobile phases. In this case, 3 different mobile phases were investigated, yielding the SEC aggregation results shown in Figures 8A through 8C . However, the good agreement in the total amount of aggregation determined by AUC analysis in Figure 8D (on the same sample in its formulation buffer) with the SEC results obtained in Figure 8B indicates that buffer system 2 is the appropriate SEC mobile phase to use to obtain accurate aggregation for this protein.
Finally, AUC results in Figure 9 show the unique selfassociating properties of a biopharmaceutical (in a specifi c buffer) as a function of its concentration. At a concentration of 0.2 mg/mL, the sedimentation coeffi cient distribution of this biopharmaceutical shows a single major peak in addition to a much smaller but faster-migrating peak ( Figure  9A ). When the concentration of the biopharmaceutical is increased to 5.9 mg/mL, the faster-moving peak becomes the major peak and moves with a slightly higher sedimentation coeffi cient ( Figure 9D ). Such a behavior illustrates the concentration-dependent aggregation properties of this biopharmaceutical. This behavior is supported by simple model-free AUC analysis that yields the weight-average sedimentation coeffi cient (S w ) shown in Figure 9 for each sample concentration. In this analysis, the S w values for this biopharmaceutical are observed to be an increasing function of concentration. This behavior is a classical diagnostic for concentration-dependent aggregation 98 and supports the results obtained by SEDFIT. In SEC analysis of this biopharmaceutical, this concentration-dependent behavior was missed because SEC results (data not shown) showed the presence of only a single peak in all cases. The ability to detect such reversible chemical-reacting systems by AUC (even when the accuracy of the computed c(s) vs s plot is lacking, owing to the dynamic nature of the aggregation process relative to the time scale of the AUC experiment) can be important in biopharmaceutical development, specifi cally when the kinetics of disassociation for the aggregated biopharmaceutical in vivo (when administered to a patient) is very slow, as mentioned in the Aggregation of Protein Biopharmaceuticals section.
ADVANTAGES OF USING AUC TO HELP ASSESS BIOPHARMACEUTICAL AGGREGATION
Using AUC to assess the aggregation of a biopharmaceutical provides several distinct advantages over using SEC:
1. The level of experimental method development required is minimal. 2. No sample preparation is required, other than possibly sample dilution to investigate the effect of protein concentration on aggregation. However, when using an analytical ultracentrifuge ' s interference optical system (the Rayleigh interferometer, 99 which is a special and useful differential refractive index detector present on the AUC XL-I that enables very accurate concentration measurements to be made on biopharmaceuticals that lack chemical groups that absorb light, that generate variable light scattering background, or that are embedded in a buffer matrix that strongly adsorbs light), some simple steps (eg, sample dialysis) may be needed to match the sample and reference solution buffer matrix. 100 This sample preparation step is required to avoid artifacts from the differential sedimentation of buffer components due to differences in the buffer concentration between the reference and sample solutions.
3. Biopharmaceuticals can be run in its exact formulation buffer (within the limits of chemical stability of the centerpiece and windows of the AUC cell) and at the formulation concentration of the biopharmaceutical, as it exists in the vial. It should be noted, however, that although very high protein concentrations (eg, 40-50 mg/mL) can be analyzed in the analytical ultracentrifuge (especially when using the 3-mm centerpiece and the Rayleigh interferometer) the effect of non-ideal thermodynamic and hydrodynamic behavior can signifi cantly limit the utility of the data obtained. Nevertheless, the ability to detect gross behavior changes and to conduct experiments at protein concentrations in the range of a few milligrams/ milliliter and to possibly 10 mg/mL without encountering a signifi cant impact from these non-ideality effects can provide qualitative insight as to what might be going on at much higher protein concentrations.
4. Several samples in different formulation buffers can be simply and accurately analyzed in the same AUC run. Typically, 7 to 8 samples can be analyzed in 1 AUC run using the 8-hole AN50Ti rotor (however, as mentioned earlier, under appropriate conditions sample throughput can be doubled 88 ).
5. The amount of surface area that a sample encounters during AUC is minimal. The only material an AUC sample encounters is the sapphire or quartz window and the Epon charcoal-fi lled plastic or aluminum centerpiece.
6. AUC can be operated over a range of speeds (from ~2 K to 60 K rpm). Hence, the molecular weight and size range that it can characterize is enormous: from molecules of only a few hundred daltons 30 to particles that are almost a micron in size. 101 , 102 In some cases, AUC analysis methods have been developed 
CONCLUSIONS
As discussed in this article and other recent publications, analytical ultracentrifuges offer new, enhanced capabilities for assessing the aggregation and homogeneity of biopharmaceuticals. 6-10 , 28-33 , 37 , 42-50 , 64 , 103 However, this is not to suggest that AUC should replace SEC. The processing of large numbers of samples on a daily basis and in a regulatorycompliant testing environment would present major challenges for AUC. Hence, at present, AUC will best service today ' s biopharmaceutical industry by supporting efforts in the development of accurate SEC methods and in the generation of important biophysical characterization information on potential biopharmaceuticals to help identify, design, and formulate new commercial drug products. Yet the task of implementing the widespread use of AUC analysis in the biopharmaceutical industry is stymied by the following 2 problems: (1) the relatively high cost of AUC instrumentation (especially for small biopharmaceutical companies), and (2) the small numbers of scientists who understand AUC analysis. The latter problem is the more challenging because for many years young scientists received little or no training in AUC analysis in academia. As a result, many biopharmaceutical scientists fi nd the science (and mathematics) associated with AUC analysis to be foreign and intimidating. It is hoped that through courses, seminars, and workshops such as those offered by Schuck (at the National Institutes of Health, Bethesda, MD, http://dbeps.ors.od.nih. gov./pbr_auc.htm ), Demeler (at the University of Texas Health Science Center at San Antonio, http://www.cauma. uthscsa.edu/ ), Cole (at the University of Connecticut Biotechnology Center, http://www.biotech.uconn.edu/auf/ ), and Beckman Coulter Inc (Fullerton, CA, http://www. beckmancoulter.com ), the sole manufacturer of the analytical ultracentrifuge, and through the published work of others, the more common use and acceptance of AUC analysis in the biopharmaceutical industry will be realized. As Howard Schachman 13 would say, " We can hardly wait! "
ACKNOWLEDGMENTS
I would like to thank the following people at Biogen Idec: Dr Stacey Traviglia for providing the SEC chromatogram in Figure 7 and Dr Veronique Bailly for providing the SEC chromatograms in Figure 8 .
